An Open-label Randomized Phase II Study to Assess the Efficacy and Safety of Nintedanib Alone or in Combination With Capecitabine for Patients With Refractory Metastatic Colorectal Cancer

Trial Profile

An Open-label Randomized Phase II Study to Assess the Efficacy and Safety of Nintedanib Alone or in Combination With Capecitabine for Patients With Refractory Metastatic Colorectal Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Nintedanib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Dec 2016 Status changed from withdrawn prior to enrolment to discontinued.
    • 27 Oct 2016 Status changed from suspended to withdrawn prior to enrolment.
    • 22 Aug 2016 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top